Research programme: LRRK2 protein inhibitors - Ipsen/Oncodesign

Drug Profile

Research programme: LRRK2 protein inhibitors - Ipsen/Oncodesign

Alternative Names: ODS 2005294; ODS200594

Latest Information Update: 27 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen; Oncodesign Biotechnology
  • Class Small molecules
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 21 Oct 2015 Preclinical trials in Parkinson's disease in France (PO)
  • 18 Dec 2012 Oncodesign and the Katholieke Universiteit Leuven enter a collaboration to co-develop LRRK2 protein inhibitors for Parkinson's disease
  • 10 Jan 2012 Early research in Parkinson's disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top